Warberg Asset Management’s Bone Biologics Corp Warrants BBLGW Stock Holding History

Warberg Asset Management’s Portfolio BBLGW Stock Details BBLGW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,290	Closed	-$1.97K	–	243
2023 Q1	$1.97K	Sell	1,290 -80	-6%	-$110	﹤0.01%	236
2022 Q4	$1.22K	Sell	1,370 -1,945	-59%	-$3.53K	﹤0.01%	259
2022 Q3	$13K	Sell	3,315 -337	-9%	-$1.86K	﹤0.01%	220
2022 Q2	$21K	Hold	3,652	–	–	﹤0.01%	182
2022 Q1	$38K	Buy	3,652 +2,352	+181%	+$31.4K	0.01%	170
2021 Q4	$27K	Buy	+1,300	New	+$32.4K	0.01%	166

Other funds holding BBLGW

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Warberg Asset Management's BBLGW Position: Q2 2023 in Review

Warberg Asset Management sold out of Bone Biologics Corp Warrants (BBLGW) in Q2 2023, closing a stake of 1,290 shares — an estimated $1.97K sold.

Warberg Asset Management first reported a position in BBLGW in Q4 2021 and held it in 6 quarters. The position peaked at $38K in Q1 2022. 1 fund tracked by Wall St. Rank holds BBLGW as of Q2 2023.

Warberg Asset Management reported no remaining Bone Biologics Corp Warrants position as of Q2 2023 after selling out during the quarter.
Warberg Asset Management sold 1,290 Bone Biologics Corp Warrants shares in Q2 2023, an estimated $1.97K.
Warberg Asset Management first reported a position in Bone Biologics Corp Warrants in Q4 2021 and held it in 6 quarters.
Warberg Asset Management's Bone Biologics Corp Warrants position peaked at $38K in Q1 2022.
1 fund tracked by Wall St. Rank held Bone Biologics Corp Warrants as of Q2 2023.

Based on Warberg Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.